dc.contributor.author | Codina, Pau | |
dc.contributor.author | Domingo, Mar | |
dc.contributor.author | Barceló, Elena | |
dc.contributor.author | Gastelurrutia, Paloma | |
dc.contributor.author | Casquete, Daniel | |
dc.contributor.author | Vila, Joan | |
dc.contributor.author | Abdul-Jawad Altisent, Omar | |
dc.contributor.author | Spitaleri, Giosafat | |
dc.contributor.author | Cediel, Germán | |
dc.contributor.author | Santiago-Vacas, Evelyn | |
dc.contributor.author | Zamora, Elisabet | |
dc.contributor.author | Ruiz-Cueto, María | |
dc.contributor.author | Santesmases, Javier | |
dc.contributor.author | de la Espriella, Rafael | |
dc.contributor.author | Pascual-Figal, Domingo A | |
dc.contributor.author | Nuñez, Julio | |
dc.contributor.author | Lupón, Josep | |
dc.contributor.author | Bayes-Genis, Antoni | |
dc.date.accessioned | 2023-04-03T11:41:33Z | |
dc.date.available | 2023-04-03T11:41:33Z | |
dc.date.issued | 2022-08 | |
dc.identifier.citation | ESC Heart Fail. 2022 Aug;9(4):2170-2180 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/15733 | |
dc.description.abstract | Prior studies have not fully characterized the haemodynamic effects of the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan in heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH). The aim of the Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device (ARNIMEMS-HFpEF) study is to assess pulmonary artery pressure (PAP) dynamics by means of implanted PAP monitors in patients with HFpEF-PH treated with sacubitril/valsartan.
This single-arm, investigator-initiated, interventional study included 14 consecutive ambulatory symptomatic HFpEF-PH patients who underwent CardioMEMS implantation prior to enrolment [mean ejection fraction 60.4 ± 7.2%, baseline mean PAP (mPAP) 33.9 ± 7.6 mmHg]. Daily PAP values were examined during three periods: a 6 week period after CardioMEMS implantation and before sacubitril/valsartan treatment (pre-ARNI), a 6 week period with sacubitril/valsartan treatment (ARNI ON), and a 6 week period of sacubitril/valsartan withdrawal (ARNI OFF). The primary endpoint was change in mPAP with and without sacubitril/valsartan. Secondary endpoints included changes in 6 min walking distance, B-line sum in lung ultrasound, and quality of life (QoL). During the study period, 1717 mPAP measurements were recorded. Between pre-ARNI vs. ARNI ON, mPAP significantly declined by -4.99 mmHg [95% confidence interval (CI) -5.55 to -4.43]. Between ARNI ON vs. ARNI OFF, mPAP significantly increased by +2.84 mmHg [95% CI +2.26 to +3.42]. Between pre-ARNI vs. ARNI ON, we found an improvement in 6 min walking distance, B-lines, and QoL. Mean loop diuretic management did not differ between periods.
Sacubitril/valsartan significantly reduced mPAP in patients with HFpEF-PH, independent of loop diuretic management, together with improvement in functional capacity, lung congestion, and QoL. Sacubitril/valsartan may be a therapeutic alternative in HFpEF-PH. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.mesh | Heart Failure | es_ES |
dc.subject.mesh | Hypertension, Pulmonary | es_ES |
dc.subject.mesh | Aminobutyrates | es_ES |
dc.subject.mesh | Arterial Pressure | es_ES |
dc.subject.mesh | Biphenyl Compounds | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Neprilysin | es_ES |
dc.subject.mesh | Quality of Life | es_ES |
dc.subject.mesh | Sodium Potassium Chloride Symporter Inhibitors | es_ES |
dc.subject.mesh | Stroke Volume | es_ES |
dc.subject.mesh | Tetrazoles | es_ES |
dc.subject.mesh | Valsartan | es_ES |
dc.title | Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 35588235 | es_ES |
dc.format.volume | 9 | es_ES |
dc.format.number | 4 | es_ES |
dc.format.page | 2170 | es_ES |
dc.identifier.doi | 10.1002/ehf2.13952 | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2055-5822 | es_ES |
dc.relation.publisherversion | 10.1002/ehf2.13952 | es_ES |
dc.identifier.journal | ESC heart failure | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Imagen Cardiovascular y Estudios Poblacionales | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.rights.accessRights | open access | es_ES |